Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

A new study that looked at how liberal vs. restrictive fluid restriction impacts health status for patients with chronic ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

A show of hands at the ACC town hall demonstrated unity as specialists investigate options for a new certifying board outside the current one or with two parent sponsors.

The largest randomized study of fluid intake restrictions showed no benefit from the restrictions, according to its senior ...

Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

GE HealthCare (Nasdaq: GEHC) today announced the U.S. launch of Flyrcado™ (flurpiridaz F 18) injection at the 2025 American ...

Albany-based nonprofit health insurer lost $168 million in 2024 largely due to changes to Medicare Wage Index, it says, ...

The number of cardiology procedures performed in ASCs is rising sharply, according to HST Pathways’ latest “State of the Industry Report.” The report surveyed 590 ASCs in 47 states. Here are four more ...

Christian T. Ruff, MD, MPH, of Brigham and Women's Faulkner Hospital, discusses new data comparing abelacimab with ...